uniQure moves closer to FDA approval as AMT-130 gene therapy shows progress for Huntington’s disease

uniQure N.V. (NASDAQ: QURE) is moving closer to what could be one of the most consequential milestones in the gene therapy space: potential FDA approval for AMT-130, its investigational one-time therapy for Huntington’s disease (HD). The company’s latest regulatory update outlines key alignments with the U.S. Food and Drug Administration (FDA) on endpoints, external controls, and manufacturing validation, setting the stage for a possible Biologics License Application (BLA) submission in early 2026.

This progress marks a defining moment for the Dutch biotech, whose stock and sentiment have been shaped by years of anticipation surrounding AMT-130. As regulatory clarity expands, so too does investor debate about whether this pioneering therapy is poised for breakthrough approval—or another drawn-out biotech journey defined by data risk and capital burn.

Why the FDA’s alignment on endpoints and external controls represents a turning point for uniQure’s AMT-130

The FDA’s acceptance of the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint for accelerated approval has changed the trajectory of the AMT-130 program. The cUHDRS is a composite tool combining motor, cognitive, and functional assessments that together capture disease progression more comprehensively than individual subscores.

Regulators also agreed that uniQure could use external control data drawn from ENROLL-HD, the world’s largest natural-history study for Huntington’s disease, to serve as a comparator arm. This move significantly reduces the need for a traditional placebo-controlled Phase III trial—saving both time and cost in a therapeutic area where recruiting large cohorts is logistically and ethically difficult.

From a statistical perspective, the company will employ propensity-score matching and longitudinal modeling to adjust for baseline differences between treated and untreated cohorts. The FDA’s willingness to entertain such modern, data-driven methods underscores its growing comfort with real-world data in rare neurological indications.

Equally pivotal is the agency’s alignment on manufacturing validation. The FDA has agreed that uniQure may leverage its existing experience from Hemgenix®—its already approved AAV-based gene therapy for hemophilia B—as a reference for AMT-130. Only a single Process Performance Qualification (PPQ) batch will be required for validation, reducing both time-to-market and cost.

Together, these alignments have provided uniQure a clearer and more achievable regulatory path than most neurological gene therapy developers have managed in recent years.

How AMT-130’s mechanism and early clinical signals are shaping expectations among researchers and investors

AMT-130 delivers a microRNA that selectively lowers mutant huntingtin (mHTT) protein levels in the brain. Delivered via adeno-associated virus (AAV5) directly into the striatum through neurosurgical infusion, the therapy aims to halt or slow the neurodegeneration characteristic of Huntington’s disease—a fatal hereditary disorder with no disease-modifying treatment to date.

Interim Phase I/II data presented earlier in 2025 showed encouraging trends: high-dose cohorts exhibited a slower rate of decline on cUHDRS over 24 months compared to matched natural-history controls. Safety outcomes were generally acceptable, with transient postoperative inflammation and no new long-term safety signals. The therapy also achieved measurable reductions in mHTT protein and neurofilament light chain levels—biomarkers indicating potential biological activity.

AMT-130 was granted Breakthrough Therapy designation in April 2025, adding to its existing RMAT and orphan-drug designations. Those endorsements reflect not only the therapy’s scientific promise but also regulatory recognition that HD represents an area of urgent unmet need.

For patients, the potential of a one-time infusion to slow or stop disease progression offers unprecedented hope. For investors, however, the excitement has been tempered by the inherent volatility of early-stage gene therapy programs—particularly those targeting complex central nervous system disorders.

What the latest stock performance and sentiment shifts reveal about market expectations for uniQure

UniQure’s equity performance in 2025 has mirrored its regulatory narrative: volatile, reactive, and deeply sentiment-driven. Shares surged in June following initial reports of FDA alignment, rising more than 40% from their spring lows as traders bet on an accelerated-approval path. Analysts at several institutions reiterated “Buy” ratings, with one consensus 12-month target hovering around USD 69—more than double the then-prevailing share price.

But optimism was short-lived. On November 3, 2025, uniQure’s shares plummeted more than 55% in premarket trading after the company disclosed that the FDA had informed them that current AMT-130 data were not adequate to support a BLA filing at this time. The agency reportedly asked for additional long-term clinical evidence before considering an approval submission.

That regulatory jolt has recalibrated market expectations dramatically. While earlier sentiment viewed AMT-130 as a front-runner for the first Huntington’s gene therapy approval, the recent setback places uniQure back in data-generation mode. Analysts now describe the outlook as “delayed but not derailed.” Many see the next 12 months as crucial for restoring credibility through robust three-year efficacy data and manufacturing readiness.

From a capital-market standpoint, uniQure’s financial position remains relatively solid, with roughly USD 409 million in cash and equivalents as of Q1 2025—enough runway to sustain operations well into 2026. Yet the sharp stock reaction underscores the thin line between regulatory promise and investor patience in the biotech sector.

How the Huntington’s disease landscape and FDA guidance are evolving around accelerated approvals

The FDA’s evolving approach to neurodegenerative disease trials has been influenced by its handling of Alzheimer’s, ALS, and rare inherited ataxias. For Huntington’s disease, the agency’s openness to novel endpoints and external controls signals a pragmatic shift—prioritizing patient access without sacrificing statistical rigor.

Still, external control data come with challenges. While ENROLL-HD’s extensive dataset offers an invaluable reference, aligning treated AMT-130 patients with historical controls introduces potential biases. The FDA’s guidance emphasizes the need for sensitivity analyses and transparent modeling to demonstrate that treatment effects are not artifacts of baseline imbalances.

For clinicians, the update underscores how real-world data and natural-history registries can increasingly complement traditional clinical trials. For biostatisticians, it highlights the growing importance of AI-assisted matching and data curation pipelines in supporting regulatory-grade evidence.

Beyond uniQure, this regulatory precedent could influence other gene therapy developers, including Wave Life Sciences and Voyager Therapeutics, which are pursuing RNA- and AAV-based approaches for neurodegenerative targets. A successful—or even conditionally successful—pathway for AMT-130 could pave the way for similar submissions in diseases once considered too complex for gene therapy.

What the latest FDA communication means for uniQure’s timeline and biotech investor confidence

The November 3 update, in which the FDA indicated AMT-130’s Phase I/II data were not yet adequate for a BLA filing, marks an inflection point. While disappointing to investors, it also provides clarity: additional follow-up and possibly expanded datasets will be necessary. The company’s stated plan remains to present full three-year data in mid-2025 and hold further regulatory discussions in late Q4.

Investor sentiment is now cautiously watchful. The accelerated-approval narrative that once fueled optimism has shifted toward a “prove-it” phase. Many institutional holders appear to be maintaining positions, suggesting belief in long-term value creation if the data ultimately validate AMT-130’s disease-modifying potential.

From a strategic perspective, uniQure’s credibility in gene therapy manufacturing—established through Hemgenix—remains an asset. The key challenge now lies in translating that credibility into clinical efficacy for a neurological target. For patient communities, the delay is frustrating but not fatal; for investors, it represents both risk and opportunity in a biotech landscape increasingly defined by data precision and regulatory nuance.

The broader implication is that AMT-130’s journey could define the next decade of neuro-gene therapy regulation. The FDA’s cautious optimism reflects both its desire to accelerate innovation and its duty to ensure clinical validity. If uniQure’s upcoming data can bridge that gap, the therapy could still emerge as the first true disease-modifying treatment for Huntington’s disease—a milestone that would reshape not just uniQure’s valuation, but the entire field of neurogenetics.